Clinical

Dataset Information

0

Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies


ABSTRACT: This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug. The purpose of this study is to evaluate the safety, determine the maximum-tolerated dose (MTD) and characterize the pharmacokinetic profile of ALT-801 in previously treated patients with progressive metastatic malignancies. ALT-801, a recombinant fusion protein with a interleukin-2 (IL-2) component, has a targeting mechanism that recognizes tumor cells with a specific tumor marker.

DISEASE(S): Lung Cancer,Melanoma,Colorectal Cancer,Bladder Cancer,Advanced Cancer,Breast Cancer,Lymphoma,Neoplasms,Ovarian Cancer,Esophagus Cancer,Colon Cancer,Head And Neck Cancer,Progressive Metastatic Malignancies,Cancer

PROVIDER: 2041748 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2022-10-05 | GSE201197 | GEO
2019-08-29 | GSE131147 | GEO
2024-01-25 | PXD047339 | Pride
| S-EPMC6472227 | biostudies-literature
| 2099056 | ecrin-mdr-crc
2022-02-17 | PXD027203 | Pride
| 2082745 | ecrin-mdr-crc
| 2286305 | ecrin-mdr-crc
| PRJNA992640 | ENA
2024-09-02 | BIOMD0000000238 | BioModels